Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Open-Label Study of LY2140023 vs Atypical Antipsychotic Standard of Care in Schizophrenia
2009-017853-36Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pomaglumetad methionil in schizophrenia (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to discontinuation due to adverse events during the first year. Started Jan 2010; status: completed.
02
Drugs
pomaglumetad methionil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2009-017853-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017853-36.